This biotechnology company develops novel antibody and protein-based therapeutics targeting cancer and cardiovascular diseases. By creating transformative therapeutic molecules, it aims to improve the quality of life for patients with significant medical needs.
Funding
$35M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cardiovascular diseases, including heart failure, and various cancers remain leading causes of death, often with limited effective treatment options and significant unmet medical needs. Current therapies may not adequately address disease progression or improve the quality of life for affected patients.
Solution
Salubris Biotherapeutics is a clinical-stage biotechnology company focused on discovering and developing novel, complex biologic therapeutics, including antibody and protein-based molecules, to address critical unmet needs in cardiovascular disease and oncology. Their research and development efforts are centered on creating first-in-class biologics that offer clinically meaningful improvements in disease burden and enhance the quality of life for patients. A key program focuses on Heart Failure, where they are developing a selective ErbB4 agonist, JK07, to improve heart function. Another key program focuses on oncology, where they are developing a 5T4-targeted ADC, JK06, for solid tumor cancers.
Target Audience
The primary target audience includes patients suffering from heart failure (both HFrEF and HFpEF) and individuals diagnosed with various solid tumor cancers, as well as the healthcare providers who treat them.
Features
- JK07: A selective ErbB4 agonist in Phase 2 clinical trials for Heart Failure with Reduced Ejection Fraction (HFrEF) and Heart Failure with Preserved Ejection Fraction (HFpEF), demonstrating a safe and tolerable profile with positive preliminary signs of efficacy.
- JK06: A 5T4-targeted Antibody-Drug Conjugate (ADC) in Phase 1 dose-escalation study for solid tumors.
- Focus on complex biologic therapeutics, including monoclonal antibodies and fusion proteins.
- Development of therapies targeting the NRG/ErbB4 pathway for myocardial development, homeostasis, and repair.
- Clinical trials designed to evaluate safety, tolerability, and efficacy in patient populations with significant unmet needs.